WVE

SEC source: 0000899243-19-021962 · doc4.xml · derivative · entry 1

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,500

Underlying: Ordinary Shares · 10,500 shares

Expires 2024-08-15

F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2020 annual general meeting or August 15, 2020.

SEC source: 0000899243-19-021967 · doc4.xml · derivative · entry 1

Verdine Gregory L. · CIK 0001572315 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,500

Underlying: Ordinary Shares · 10,500 shares

Expires 2024-08-15

F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2020 annual general meeting or August 15, 2020.

SEC source: 0000899243-19-021963 · doc4.xml · derivative · entry 1

TAKANASHI KEN · CIK 0001657768 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,500

Underlying: Ordinary Shares · 10,500 shares

Expires 2024-08-15

F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2020 annual general meeting or August 15, 2020.

SEC source: 0000899243-19-021959 · doc4.xml · derivative · entry 1

Miura Koji · CIK 0001657766 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,500

Underlying: Ordinary Shares · 10,500 shares

Expires 2024-08-15

F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2020 annual general meeting or August 15, 2020.

SEC source: 0000899243-19-021293 · doc4.xml · derivative · entry 3

Baldry Mark · CIK 0001644137 · Chief Commerical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Ordinary Shares · 25,000 shares

Expires 2029-08-05

F3 · derivative.exercise_date: The option vests as to 25% of the shares on August 5, 2020 and the remainder vests quarterly thereafter until August 5, 2023.

SEC source: 0000899243-19-021293 · doc4.xml · nonDerivative · entry 2

Baldry Mark · CIK 0001644137 · Chief Commerical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,000

F2 · shares: Consists of RSUs. The RSUs vest as to 50% on August 5, 2020 and 50% on August 5, 2021.

SEC source: 0000899243-19-021293 · doc4.xml · nonDerivative · entry 1

Baldry Mark · CIK 0001644137 · Chief Commerical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on August 5, 2020 through August 5, 2023.

SEC source: 0000899243-19-019395 · doc4.xml · nonDerivative · entry 2

Panzara Michael A. · CIK 0001679039 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,330

F1 · kind: Consists of sale of restricted share units (RSUs) effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019.

SEC source: 0000899243-19-019395 · doc4.xml · nonDerivative · entry 1

Panzara Michael A. · CIK 0001679039 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,775

F1 · kind: Consists of sale of restricted share units (RSUs) effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2019.

F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $26.25 to $27.21 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-19-008404 · doc4.xml · derivative · entry 6

BOLNO PAUL · CIK 0001657710 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 322,778

Underlying: Ordinary Shares · 50,000 shares

Expires 2025-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2018.

F6 · derivative.exercise_date: These share options are fully vested.

SEC source: 0000899243-19-008404 · doc4.xml · nonDerivative · entry 5

BOLNO PAUL · CIK 0001657710 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 331,209

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2018.

F5 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $45.92 to $46.00 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-19-008404 · doc4.xml · nonDerivative · entry 4

BOLNO PAUL · CIK 0001657710 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 332,972

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2018.

F4 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $44.90 to $45.88 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-19-008404 · doc4.xml · nonDerivative · entry 3

BOLNO PAUL · CIK 0001657710 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 341,209

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2018.

F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $45.78 to $46.03 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-19-008404 · doc4.xml · nonDerivative · entry 2

BOLNO PAUL · CIK 0001657710 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 346,274

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2018.

F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $44.78 to $45.77 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-19-008404 · doc4.xml · nonDerivative · entry 1

BOLNO PAUL · CIK 0001657710 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 381,209

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2018.

SEC source: 0000899243-19-007113 · doc4.xml · nonDerivative · entry 2

Panzara Michael A. · CIK 0001679039 · Franchise Lead, Neurology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,388

F2 · kind: Consists of sale of RSUs effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2018.

SEC source: 0000899243-19-007110 · doc4.xml · nonDerivative · entry 1

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,868

F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2020 through February 15, 2023.

SEC source: 0000899243-19-007106 · doc4.xml · nonDerivative · entry 1

Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,245

F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2020 through February 15, 2023

SEC source: 0000899243-19-007112 · doc4.xml · nonDerivative · entry 1

BOLNO PAUL · CIK 0001657710 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 331,209

F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2020 through February 15, 2023.

SEC source: 0000899243-19-007114 · doc4.xml · nonDerivative · entry 1

Regnante Keith · CIK 0001682068 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,186

F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2020 through February 15, 2023.

SEC source: 0000899243-19-007113 · doc4.xml · nonDerivative · entry 1

Panzara Michael A. · CIK 0001679039 · Franchise Lead, Neurology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,388

F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2020 through February 15, 2023.

SEC source: 0000899243-19-004462 · doc4.xml · nonDerivative · entry 1

Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,245

F1 · kind: On February 19, 2019, the reporting person sold 2,055 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2019. These sales were made pursuant to a 10b5-1 Trading Plan.

F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $36.83 to $37.4865 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-19-004460 · doc4.xml · nonDerivative · entry 1

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,368

F1 · kind: On February 19, 2019, the reporting person sold 1,709 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2019. These sales were made pursuant to a 10b5-1 Trading Plan.

F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $36.83 to $37.4713 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.1

SEC source: 0000899243-19-004464 · doc4.xml · nonDerivative · entry 2

BOLNO PAUL · CIK 0001657710 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 271,209

F1 · kind: On February 19, 2019, the reporting person sold 7,733 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2019. These sales were made pursuant to a 10b5-1 Trading Plan.

F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $37.4638 to $37.4672 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-19-004464 · doc4.xml · nonDerivative · entry 1

BOLNO PAUL · CIK 0001657710 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 271,328

F1 · kind: On February 19, 2019, the reporting person sold 7,733 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2019. These sales were made pursuant to a 10b5-1 Trading Plan.

SEC source: 0000899243-19-004466 · doc4.xml · nonDerivative · entry 1

Panzara Michael A. · CIK 0001679039 · Franchise Lead, Neurology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,388

F1 · kind: On February 19, 2019, the reporting person sold 1,837 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2019. These sales were made pursuant to a 10b5-1 Trading Plan.

F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $36.83 to $37.4713 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-19-004467 · doc4.xml · nonDerivative · entry 1

Regnante Keith · CIK 0001682068 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,686

F1 · kind: On February 19, 2019, the reporting person sold 1,298 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2019. These sales were made pursuant to a 10b5-1 Trading Plan.

F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $36.83 to $37.4582 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0001144204-19-003160 · tv511718_4.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, LLC · CIK 0001346824 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 7,775,207

F1 · balance_after: Following the reported transactions, RA Capital Healthcare Fund, L.P. (the "Fund") held 6,805,182 shares and 970,025 shares held by a separately managed account (the "Account").

F2 · ownership.nature: RA Capital Management, LLC (the "Adviser") is the general partner of the Fund and the investment adviser of the Account. Peter Kolchinsky is a director of the issuer and is the sole manager of the Adviser. In their respective capacities, each of Dr. Kolchinsky and the Adviser may be deemed to beneficially own the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934.

F3 · ownership.nature: The Adviser and Dr. Kolchinsky disclaim beneficial ownership of the reported securities for purposes of Rule 16a-1(a)(1) under the Exchange Act in reliance on Rule 16a-1(a)(1)(v) and (vii), respectively. The filing of this Form 4 shall not be construed as an admission that either the Adviser or Dr. Kolchinsky is or was, for purposes of Rule 16a-1(a)(1) under the Exchange Act, the beneficial owner of any of the securities reported herein. Dr. Kolchinsky and the Adviser disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a)(2) under the Exchange Act except to the extent of their pecuniary interest therein.

SEC source: 0000899243-18-029157 · doc4.xml · nonDerivative · entry 2

Verdine Gregory L. · CIK 0001572315 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,039

F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $39.33 to $39.53 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price..

SEC source: 0000899243-18-029157 · doc4.xml · nonDerivative · entry 1

Verdine Gregory L. · CIK 0001572315 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,339

F1 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $38.15 to $39.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-18-025322 · doc4.xml · derivative · entry 6

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,997

Underlying: Ordinary Shares · 10,543 shares

Expires 2025-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.

F2 · derivative.exercise_date: The share option represented a right to purchase a total of 126,174 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0000899243-18-025322 · doc4.xml · nonDerivative · entry 4

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,077

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.

SEC source: 0000899243-18-025322 · doc4.xml · nonDerivative · entry 3

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,620

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.

SEC source: 0000899243-18-025322 · doc4.xml · derivative · entry 5

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,540

Underlying: Ordinary Shares · 1,032 shares

Expires 2025-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.

F2 · derivative.exercise_date: The share option represented a right to purchase a total of 126,174 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0000899243-18-025322 · doc4.xml · nonDerivative · entry 2

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,077

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.

SEC source: 0000899243-18-025322 · doc4.xml · nonDerivative · entry 1

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,109

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.

SEC source: 0000899243-18-025318 · doc4.xml · derivative · entry 3

Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,542

Underlying: Ordinary Shares · 3,000 shares

Expires 2025-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.

F2 · derivative.exercise_date: The incentive share option initially represented a right to purchase a total of 158,042 ordinary shares, 25% of which became exercisable on August 1, 2015, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0000899243-18-025318 · doc4.xml · nonDerivative · entry 2

Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,300

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.

SEC source: 0000899243-18-025318 · doc4.xml · nonDerivative · entry 1

Vargeese Chandra · CIK 0001657675 · Senior VP, Drug Discovery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.

SEC source: 0000899243-18-025320 · doc4.xml · derivative · entry 3

Regnante Keith · CIK 0001682068 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,500

Underlying: Ordinary Shares · 29,500 shares

Expires 2026-08-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.

F2 · derivative.exercise_date: The share option represented a right to purchase a total of 120,000 ordinary shares, 25% of which became exercisable on August 16, 2017, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0000899243-18-025320 · doc4.xml · nonDerivative · entry 2

Regnante Keith · CIK 0001682068 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,984

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.

SEC source: 0000899243-18-025320 · doc4.xml · nonDerivative · entry 1

Regnante Keith · CIK 0001682068 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,484

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.

F2 · price: The share option represented a right to purchase a total of 120,000 ordinary shares, 25% of which became exercisable on August 16, 2017, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0000899243-18-022514 · doc4.xml · derivative · entry 1

HENRY CHRISTIAN O · CIK 0001263805 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Ordinary Shares · 9,000 shares

Expires 2023-08-13

F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 13, 2019.

SEC source: 0000899243-18-022515 · doc4.xml · derivative · entry 1

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Ordinary Shares · 9,000 shares

Expires 2023-08-13

F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 13, 2019.

SEC source: 0000899243-18-022506 · doc4.xml · derivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Ordinary Shares · 9,000 shares

Expires 2023-08-13

F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 13, 2019.

SEC source: 0000899243-18-022513 · doc4.xml · derivative · entry 1

Verdine Gregory L. · CIK 0001572315 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Ordinary Shares · 9,000 shares

Expires 2023-08-13

F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 13, 2019.

SEC source: 0000899243-18-022512 · doc4.xml · derivative · entry 1

TAKANASHI KEN · CIK 0001657768 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Ordinary Shares · 9,000 shares

Expires 2023-08-13

F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 13, 2019.

SEC source: 0000899243-18-022507 · doc4.xml · derivative · entry 1

Miura Koji · CIK 0001657766 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Ordinary Shares · 9,000 shares

Expires 2023-08-13

F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on August 13, 2019.

SEC source: 0000899243-18-019753 · doc4.xml · derivative · entry 5

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,572

Underlying: Ordinary Shares · 24,496 shares

Expires 2025-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.

F4 · derivative.exercise_date: The share option represented a right to purchase a total of 126,174 ordinary shares, 25% of which became exercisable on April 15, 2015, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0000899243-18-019753 · doc4.xml · nonDerivative · entry 4

Francis Chris · CIK 0001657709 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,077

F1 · kind: The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018.

F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $38.10 to $38.25 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.